William Thomas Hrinivich1, Douglas A Hoover2, Kathleen Surry2, Chandima Edirisinghe3, Jacques Montreuil3, David D'Souza4, Aaron Fenster5, Eugene Wong6. 1. Medical Biophysics, The University of Western Ontario, London, ON, Canada; Robarts Imaging Research Laboratories, London, ON, Canada. Electronic address: whrinivi@uwo.ca. 2. Medical Biophysics, The University of Western Ontario, London, ON, Canada; Oncology, University of Western Ontario, London, ON, Canada; London Regional Cancer Program, London, ON, Canada. 3. Robarts Imaging Research Laboratories, London, ON, Canada. 4. Oncology, University of Western Ontario, London, ON, Canada; London Regional Cancer Program, London, ON, Canada. 5. Medical Biophysics, The University of Western Ontario, London, ON, Canada; Robarts Imaging Research Laboratories, London, ON, Canada; Oncology, University of Western Ontario, London, ON, Canada; Physics and Astronomy, University of Western Ontario, London, ON, Canada. 6. Medical Biophysics, The University of Western Ontario, London, ON, Canada; Oncology, University of Western Ontario, London, ON, Canada; London Regional Cancer Program, London, ON, Canada; Physics and Astronomy, University of Western Ontario, London, ON, Canada.
Abstract
PURPOSE: Conventional transrectal ultrasound guided high-dose-rate prostate brachytherapy (HDR-BT) uses an axially acquired image set for organ segmentation and 2D sagittal images for needle segmentation. Sagittally reconstructed 3D (SR3D) transrectal ultrasound enables both organ and needle segmentation and has the potential to reduce organ-needle alignment uncertainty. This study compares the accuracy of needle tip localization between the conventional 2D sagittally assisted axially reconstructed (SAAR) and SR3D approaches. METHODS AND MATERIALS: Twelve patients underwent SAAR-guided HDR-BT, during which SR3D images were acquired for subsequent segmentation and analysis. A total of 183 needles were investigated. Needle end-length measurements were taken, providing a gold standard for insertion depths. Dosimetric impact of insertion depth errors (IDEs) on clinical treatment plans was assessed. RESULTS: SR3D guidance provided statistically significantly smaller IDEs than SAAR guidance with a mean ± SD of -0.6 ± 3.2 mm and 2.8 ± 3.2 mm, respectively (p < 0.001). Shadow artifacts were found to obstruct the view of some needle tips in SR3D images either partially (12%) or fully (10%); however, SR3D IDEs had a statistically significantly smaller impact on prostate V100% than SAAR IDEs with mean ± SD decreases of -1.2 ± 1.3% and -6.5 ± 6.7%, respectively (p < 0.05). CONCLUSIONS: SR3D-guided HDR-BT eliminates a source of systematic uncertainty from the SAAR-guided approach, providing decreased IDEs for most needles, leading to a significant decrease in dosimetric uncertainty. Although imaging artifacts can limit the accuracy of tip localization in a subset of needles, we identified a method to mitigate these artifacts for clinical implementation.
PURPOSE: Conventional transrectal ultrasound guided high-dose-rate prostate brachytherapy (HDR-BT) uses an axially acquired image set for organ segmentation and 2D sagittal images for needle segmentation. Sagittally reconstructed 3D (SR3D) transrectal ultrasound enables both organ and needle segmentation and has the potential to reduce organ-needle alignment uncertainty. This study compares the accuracy of needle tip localization between the conventional 2D sagittally assisted axially reconstructed (SAAR) and SR3D approaches. METHODS AND MATERIALS: Twelve patients underwent SAAR-guided HDR-BT, during which SR3D images were acquired for subsequent segmentation and analysis. A total of 183 needles were investigated. Needle end-length measurements were taken, providing a gold standard for insertion depths. Dosimetric impact of insertion depth errors (IDEs) on clinical treatment plans was assessed. RESULTS: SR3D guidance provided statistically significantly smaller IDEs than SAAR guidance with a mean ± SD of -0.6 ± 3.2 mm and 2.8 ± 3.2 mm, respectively (p < 0.001). Shadow artifacts were found to obstruct the view of some needle tips in SR3D images either partially (12%) or fully (10%); however, SR3D IDEs had a statistically significantly smaller impact on prostate V100% than SAAR IDEs with mean ± SD decreases of -1.2 ± 1.3% and -6.5 ± 6.7%, respectively (p < 0.05). CONCLUSIONS: SR3D-guided HDR-BT eliminates a source of systematic uncertainty from the SAAR-guided approach, providing decreased IDEs for most needles, leading to a significant decrease in dosimetric uncertainty. Although imaging artifacts can limit the accuracy of tip localization in a subset of needles, we identified a method to mitigate these artifacts for clinical implementation.
Authors: Anouk A M A van der Aa; Christophe K Mannaerts; Hans van der Linden; Maudy Gayet; Bart Ph Schrier; Massimo Mischi; Harrie P Beerlage; Hessel Wijkstra Journal: World J Urol Date: 2018-02-01 Impact factor: 4.226